Josh Ofman, M.D., M.S.H.S., is President at GRAIL. Josh serves as Chairman of the Board of Directors of EveryONE Medicines, a company dedicated to precision medicine for rare genetic diseases. He has previously served on the Board of Directors of Cell BT, Inc, an immunotherapy company.
Previously, Josh spent more than 15 years at Amgen, his last role being Senior Vice President, Global Value, Access and Policy. Prior to that, Josh was a faculty member in the Department of Medicine and Health Services Research at University of California, Los Angeles (UCLA) School of Medicine, Division of Digestive Diseases at Cedars-Sinai Medical Center, as well as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp. Josh holds a B.A. in history and philosophy of science from the University of California, Berkeley, and an M.D. from the University of California, Irvine, School of Medicine. Josh completed his medical training at the UCLA School of Medicine divisions of Internal Medicine and Digestive Diseases, where he also completed the NRSA Primary Care Research Fellowship in collaboration with the RWJ Clinical Scholars Program. Josh also received a Masters of Science in Health Services Research (MSHS) from the UCLA School of Public Health.
